We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Oxford Nanopore Technologies Plc | ONT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 3.65 | 3.92% | 96.75 | 14:11:26 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 93.95 | 93.95 | 97.35 | 93.10 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 15/4/2024 16:51 by yasx Brucie,I will set out my analysis on ONT in due course. 74Tom, I bear you no ill will. I merely point out that you are well out of your depth when it comes to investing. You really ought to buy a tracker rather than dispensing advice. Of course, any experienced and seasoned investor will see right through it, but novice plums may be enticed by some of the baseless guff you churn out. I have encountered you on perhaps a dozen or so threads. Where you have been bearish (invariably unjustifiably so) the shares have rocketed. When you have been relentlessly bullish, the shares have collapsed. Even more alarmingly, on each occasion it was explained to you in advance why your reasons for being bullish/bearish had no merit. I therefore take your opinion very seriously with a view to doing the exact opposite. You should do the same - it will dramatically improve your performance. Hope that helps. |
Posted at 13/4/2024 13:44 by brucie5 Oakbloke's recent comment:Detecting disease I see positive news about genetic breakthroughs in the potential detection of diseases like cancer, this week, but new approaches to its treatment too. It appears to further demonstrate how genetics will profoundly change the world in the years ahead. Yet Oxford Nanopore reaches new lows yesterday. The disconnect between investor sentiment and what I see in terms of their technical and commercial progress are quite disconnected. I prefer to hold ONT through the IP Group (since this is at a discount) but do feel the longer-term opportunity in this area is not appreciated by the market - yet. |
Posted at 22/1/2024 07:34 by bamboo2 Expansion of leadership team22 January 2024 Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces the expansion of the leadership team to support the business in its next phase of growth. Following a comprehensive search process, Nick Keher has been appointed as Chief Financial Officer ("CFO") and Director of Oxford Nanopore, effective 22 January 2024. Nick will succeed Tim Cowper, who moves into a new role as Chief Operating Officer ("COO") after performing both the role of CFO and fulfilling most of the responsibilities typically assigned to a COO for the past five years. Nick is an experienced life sciences CFO, having previously served as CFO of Clinigen Group and Benevolent AI. Prior to his CFO roles he gained extensive experience in the life sciences industry serving as Managing Director and Head of the European healthcare equity research team at Royal Bank of Canada (RBC) and before that held roles at Investec and GSK after switching from practising pharmacy. Nick comes to the role with significant experience of financial leadership of complex, scientific businesses, and has a deep understanding of capital markets. In his role as CFO, Nick will have responsibility for the Group's finance function and investor relations. In his new role as COO, Tim Cowper will lead the development of Oxford Nanopore's expanding international footprint and operations, including day to day operational functions such as manufacturing, tech transfer, IT, supply chain, global distribution, EHS and set up and management of international facilities. There will be a transition period to ensure a smooth handover and the efficient completion of the Company's 2023 audit and full year financial results. Going forward in his role as COO, Tim will continue to work closely with the new CFO to drive operational performance and margin enhancement. Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, commented: "We are delighted to welcome Nick as CFO. His experience and expertise of public company financial leadership in an innovative business environment will support our sustainable growth towards profitability. With his scientific background, he also understands the specific opportunities for life science companies. These combine with a passion to deliver impact for all of our stakeholders. I am excited to be working with Nick to drive value creation in the coming years." "I would also like to thank Tim for his leadership as CFO - for not only building and managing our financial function through our IPO process and driving our transition to a public company, but also leading many aspects of our operations in recent years. As we continue to scale the business and enhance our supply chain to meet growing demand for our products, Tim's expertise will continue to be a significant asset to the business, and I look forward to continuing to work with him in his new role as COO" Nick Keher, Chief Financial Officer of Oxford Nanopore, commented: " This is a great opportunity to join a global life sciences company with a unique, best-in-class technology platform and an ambitious vision for the future. I am delighted to be joining Gordon and the team at such an exciting time in the company's growth journey and I look forward to working together to deliver the business strategy and to create long-term shareholder value." Tim Cowper, Chief Operating Officer of Oxford Nanopore, commented: "I am excited to be moving into this new COO role, which is critical as we further develop our sophisticated operations to support expanding customer demand. Now is a good time to enhance our management team to build on the significant growth that we have achieved over the last five years. Nick's diverse experience will help enable us to scale Oxford Nanopore to reach new heights and I look forward to working with him in this next stage of our development." During the past five years, Nick Keher has been a director of Clinigen Group. |
Posted at 15/1/2024 13:46 by gisjob2 Potential investors may as well sit on the sidelines for a bit and watch how low it goes, timing is everything. |
Posted at 15/1/2024 09:27 by brucie5 £ corridor moves very quickly each way. But whereas this looked like a temporary visitor to the upper range, it's now looking to test how low. Not quite sure what frightened investors since I see no substantive change to growth in revenues or cash runway, what am I missing..? |
Posted at 09/1/2024 11:33 by keyno PR doesn't seem to be their strong point. Too busy trumping the science to their peers, which is fine but this is a plc and investors count. |
Posted at 19/12/2023 14:25 by bamboo2 19 December 2023Oxford Nanopore Technologies plc Appoints Two Non-Executive Directors Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Group"), the company delivering a new generation of nanopore-based molecular sensing technology, is pleased to announce that Dr Sarah Fortune and Dr Heather Preston will be joining the Group as Non-Executive Directors with effect from 19 December 2023. Sarah Gordon Wild and Wendy Becker, both non-executive directors of the Company, announced their retirement from Board, with effect from today and at the conclusion of the AGM in 2024, respectively. As a Professor of Immunology and Infectious Diseases at the Harvard T.H. Chan School of Public Health in Boston, Dr Sarah Fortune brings deep expertise in genomic diagnostics and multi-omics approaches to infectious disease, including at the intersection of human genetics. Her world-leading research has focused on understanding how Tuberculosis (TB) mutates to become drug resistant using a combination of single cell, genetic, and genomic approaches, including nanopore sequencing. In 2019, she led one of three labs awarded funding by the US National Institutes of Health to establish a new center for immunology research to accelerate progress in TB vaccine development - work that remains ongoing. Oxford Nanopore will draw on Sarah's rich experience as the company seeks to develop more sequencing-based applications in the clinical space, including its first sequencing-based test for drug-resistant TB. Sarah holds a Doctor of Medicine from Columbia University and a Bachelor of Science in biology from Yale University. Heather joins the board at a time when Oxford Nanopore's platform and its latest Q20+ chemistry have delivered profound developments in system performance, including accuracy and data yield, positioning it for ambitious growth. She brings more than 30 years of experience in healthcare, as a scientist, physician, McKinsey management consultant and long-time investor in biotech and the life sciences, most recently as a Managing Partner of Pivotal BioVentures based in San Francisco. She has been a director of more than 18 private and public technology-based healthcare companies, where she was involved in designing and implementing effective scaling strategies. Oxford Nanopore will draw on her expertise as it looks to deliver long-term growth and shareholder value. Heather currently sits on the Boards of Oxford Biomedica plc, Oxford Science Enterprises plc and Azura Opthalmics. Heather holds a Doctor of Medicine from the University of Oxford and a Bachelor of Science degree in biochemistry from St Bartholomew's Hospital Medical School at the University of London. Sarah Gordon Wild, a non-executive director of the Company and the non-executive responsible for workforce engagement, will retire from the Oxford Nanopore Board with effect from today, having served for nine years. Kate Priestman will succeed Sarah as the non-executive director responsible for workforce engagement. Wendy Becker, a non-executive director, has informed the Board that she will not stand for re-election at the next AGM but will remain a committed supporter of the Company. Duncan Tatton-Brown, Chair of Oxford Nanopore, said : "We are extremely pleased to welcome Sarah and Heather on the board as Non-Executive Directors of Oxford Nanopore. These are two leaders in their respective fields: Sarah's understanding of the sector, the technology and Oxford Nanopore's aspirational markets position her as an ideal resource to support the company's move into the clinical space. Heather's incredible breadth of experience, in addition to her understanding of the investor mindset, will provide a valuable voice on the board as the company looks to scale whilst delivering shareholder value. I would also like to thank our outgoing non-executive directors, Sarah and Wendy, for their outstanding support and contribution during their tenure." Sarah Fortune, incoming Non-Executive Director of Oxford Nanopore, said: " Oxford Nanopore's technology is best-in-class - beautiful, high-performing and unique in its distributed model. I'm excited to contribute by helping the company achieve its vision of distributed sequencing, both in resource-limited locations and across hospitals and other healthcare settings. This is a complex opportunity that will require engagement from multiple stakeholder groups, and I also look forward to supporting the company by applying my passion for bringing people together across disciplines to enable Oxford Nanopore's ambitious clinical vision." Heather Preston, incoming Non-Executive Director of Oxford Nanopore, said: "This is an exciting time in Oxford Nanopore's growth journey. The company has done a phenomenal job in establishing the technology in the genomics research market and is now at the point of being able to scale in a significant way. I look forward to contributing to this next phase by offering a strategic sounding board to support the company's decision-making, prioritisation and identification of the most effective ways to grow and deliver value." Gordon Sanghera, Chief Executive Officer of Oxford Nanopore, said : "Sarah and Heather bring substantial experience to support Oxford Nanopore's next phase of growth in complementary ways. Sarah's depth of knowledge in human genetics and infectious disease, in addition to her clinical background, will be critical to us as we create new opportunities for sequencing in clinical and applied markets. Heather's expertise both as a clinician and company builder will help us prioritise effectively for growth and continue to deliver value. I also want to thank outgoing non-executive directors Sarah and Wendy for their time, insight and guidance during their tenure on the board. We appreciate their significant contributions and wish them well on their next chapter." |
Posted at 13/11/2023 23:29 by bamboo2 Oxford Nanopore to participate in upcoming investor conferences13 November 2023 Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, today announces that management will be participating in the following upcoming investor conferences: -- Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, 16 November 2023 in New York, USA -- J.P. Morgan UK Leaders Conference on Tuesday, 21 November 2023 in London, UK -- Berenberg European Conference on Thursday, 7 December 2023 in Surrey, UK Gordon Sanghera, Chief Executive Officer, will participate in an analyst led fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, 16 November at 11:00am ET/ 4:00pm GMT. A live webcast of the event can be accessed at the company's investor relations page at: A replay will be available via the same link following the event. |
Posted at 21/10/2023 07:26 by bamboo2 Oxford Nanopore Technologies Outlines Plans to Expand Presence in Clinical, Applied MarketsOct 20, 2023 H Zhang Premium Use link for complete article NEW YORK – Hosting its inaugural Capital Markets Day event in London on Thursday, Oxford Nanopore Technologies delineated its ambition and strategies to further penetrate the clinical and applied markets with its nanopore sequencers. The company set the stage for the webcast event, which was open to institutional investors and financial analysts, by announcing its newly minted collaboration with Mayo Clinic and a £70 million ($84.6 million) strategic investment deal from French in vitro diagnostics firm BioMérieux. "As clinical lab networks globally are expanding, we see this as a key opportunity for nanopore sequencing to enter clinical and diagnostics markets," Emma Stanton, Oxford Nanopore's Clinical VP, told investors. According to Stanton, the company's collaboration with Mayo will first focus on breast cancer, specifically for the detection of BRAC1 and BRCA2 mutations. The collaborators are also interested in working on sequencing assays for rare cancers and infectious diseases. For its partnership with BioMérieux, Stanton said the companies are working together to roll out a nanopore sequencing-based test for the rapid identification and characterization of drug-resistant tuberculosis. Besides that, she said they are working to validate nanopore data on BioMérieux's EPISeq software, which is used for hospital infectious disease surveillance and outbreak monitoring. Furthermore, Stanton said Oxford Nanopore and BioMérieux will co-develop an IVD reflex test for clinical pathogen identification using targeted amplicon sequencing. "We always look for things that are faster, give more actionable information, and are easier to use," said Mark Miller, executive vice president and chief medical officer of BioMérieux. "It's natural for us to then take the next step and want to collaborate and develop products [with Oxford Nanopore] that really start impacting patients and infectious diseases." When asked by investors whether nanopore sequencing would undermine the company's existing BioFire multiplex PCR platform for infectious disease testing, Miller asserted that the former is "not cannibalistic at all" but rather "very complimentary and additive" to the company's product portfolio. "I don't think that with multiplex PCR you are going to achieve the degree of confidence in tuberculosis and tuberculosis [antibiotic] resistance that you will with nanopore sequencing," he said. "Nanopore sequencing gives you a vast number of genes and mutations that are relevant for antibiotic resistance on the most commonly used drugs, which we cannot obtain right now with multiplex PCR, and we are not going for." Overall, Stanton said the newly announced partnerships fit into the four pillars of Oxford Nanopore''s clinical strategy. These include collaborating with leading clinical institutions, deploying a dedicated clinical commercial sales team, developing end-to-end diagnostic solutions, and forging commercial partnerships with diagnostics firms that have established expertise, commercial presence, and market access. Additionally, she pointed out that the top three clinical and diagnostic market segments for Oxford Nanopore are oncology, human genetics diseases, and infectious disease. Still, all of Oxford Nanopore's products currently are developed for research use only, although labs can leverage them to develop and validate their own laboratory-developed tests (LDTs), Stanton said. To that end, she noted that the company will eventually need to have a "more prescribed and documented approach" for its products to achieve regulatory compliance such as IVDR marking and US Food and Drug Administration approval. However, the company declined to comment on which product it plans to seek regulatory approval for first, and it did not disclose a concrete timeline. During the event, Louisa Ludbrook, Oxford Nanopore's VP of commercial market development, accentuated the company's so-called Q-Line sequencing portfolio, which includes ISO9001-certified, locked-down versions of instruments and sample prep reagents to help industrial or clinical customers who desire to implement long-term and stabilized nanopore sequencing workflows. She also highlighted the company's ongoing partnerships in industrial markets. These include a collaboration with PathoQuest, a next-generation sequencing-based biosafety testing firm, to commercialize tests for biomanufacturing quality control — both good manufacturing practices (GMP)-validated and non-GMP. According to her, the non-GMP assay is now available while the GMP-validated test is expected to launch in early 2024. In addition, she said the company is working with the Base facility within the University of Queensland in Australia for nanopore sequencing-based mRNA vaccine quality control testing. "Together we'll develop a rapid, comprehensive direct RNA sequencing test suitable for industry use, and we're currently in discussions regarding commercial evaluation of this test," Ludbrook told investors. As Oxford Nanopore moves into the clinical diagnostic and applied markets, the company is also focusing heavily on partnerships and collaborations to share resources, build new nanopore sequencing-based products, and equally reap the benefits, said Oxford Nanopore's senior VP of corporate and business development John Schoellerman. It remains to be seen how much penetration into the clinical market the company can achieve in the near term, especially given the increasingly competitive next-generation sequencing landscape. In 2021, the company established a subsidiary called Oxford Nanopore Diagnostics to help develop validated clinical diagnostic tools harnessing nanopore sequencing. However, the company has largely remained quiet since its inception, and Oxford Nanopore's 2022 annual report listed the subsidiary's principal activity as "dormant." Oxford Nanopore did not respond to a request to comment on the future role Oxford Nanopore Diagnostics will play in helping the company go after clinical markets. When asked about what percentage of the company's current revenues are directly related to the clinical diagnostic segments during the Q&A portion of the event, CEO Gordon Sanghera said, "If we define clinical as not discovery and translational, then I would say very little." "It's too early to figure out what that looks like, as we're at the beginning in the foothills of these tests," he added. JP Morgan analyst James Gordon, who attended the event, wrote in a note to investors that it feels like the company "has turned a corner" with technological development now mostly complete and commercialization stepping up. "Though we believe there is still further detail to be fleshed out on this expansion, we see the company as well placed to deliver very strong topline growth for many years and we also came away with increased confidence in the company's ability to also deliver on the plans to reach profitability," Gordon noted. Commenting on competition in the nanopore sequencing space, Sanghera said while there is a rumor that Roche might launch a platform imminently, "we have not seen anything yet." Still, he said the company's "highly differentiated platform has significant first-mover advantage," and its "evergreen" IP portfolio has managed to "defend our position and block entrants." In that regard, he also pointed to upcoming product launches, including TurBot, a benchtop device capable of "fully hands off" sample extraction, library prep, sequencing, and data analysis, as well as TraxIon, a hand-held device also capable of carrying out the end-to-end nanopore sequencing workflow. He also teased the audience with a so-called voltage chip that the company is developing, which will come with 10,000 to 100,000 channels and "ultimately lead to a one-hour, $10 genome." "Don't ask me when that's going to happen," Sanghera said. "It's three to five years out." |
Posted at 08/6/2023 16:08 by bamboo2 IP Group - Life Sciences investor updateIP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it will hold a life sciences investor update on Thursday June 15 2023 featuring Dr Gordon Sanghera, CEO of Oxford Nanopore Technologies plc, and Professor Sir Peter Donnelly, CEO of portfolio company Genomics . The event will be hosted by CEO Greg Smith and Dr Sam Williams, Managing Partner of Life Sciences at IP Group, and, as announced on 20 April 2023, will be followed by the Group's Annual General Meeting at 11am. Further details of the event and how to register can be found here: bit.ly/3oUjNqb . The update will also be available remotely through the Investor Meet Company platform. Questions can be submitted in advance of the event via the Investor Meet Company Platform up to 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free via: . Investors who already follow IP Group plc on the Investor Meet Company platform will automatically be invited. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
